Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: Dasatinib

Registration Number: NCT00339144

Lead Sponsor: Bristol-Myers Squibb

Brief Summary: The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 16

Inclusion Criteria

Performance status (general conditions) specified by the Eastern Cooperative Oncology Group: 0-2
Histologic or cytologic diagnosis of a solid tumor which has progressed on or following standard therapies (including relapsed disease) or for which no standard therapy exists.
men and women, ages 20 and over
women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 3 months after the study in such a manner that the risk of pregnancy is minimized
Adequate hepatic function

Exclusion Criteria

Participants who are eligible and willing to undergo transplantation at pre- study.
Women who are pregnant or breastfeeding with known brain metastasis or symptoms of brain metastasis
Uncontrolled or significant bleeding disorder unrelated to a primary tumor
Dementia or mental illness that would prohibit understanding or giving informed consent.
Severe allergy to drugs required for appropriate supportive care of patients in this study.
History of gastrointestinal surgery or of any digestive disorder which has the potential to inhibit absorption of the study drug.
Pleural effusion > Grade 1
Patient with dysphagia
Does not agree to blood/blood products transfusion(s)
Donated blood over 200 mL within 4 weeks prior to the start of study therapy
Medication that known to have a risk of causing Torsade de pointes
Participants who are compulsorily detained for legal reasons or treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Dasatinib (200 mg)	Dasatinib	-
Dasatinib (100 mg)	Dasatinib	-
Dasatinib (150 mg)	Dasatinib	-

Primary Outcome Measures

Name	Time	Method
Maximum Tolerated Dose (MTD) and Maximum Acceptable Dose (MAD) of Dasatinib as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to Dasatinib Treatment	From start of the treatment i.e.Day 1 to end of Cycle 1 i.e. Day 30 (4 weeks)	MAD: highest dose level at which \>=1 DLTs were reported, MTD: dose one step lower than MAD. DLT: any of the following considered related to dasatinib during course 1:Grade 3(dose reduction by 1 dose level)/Grade 4:recurring nausea, vomiting or diarrhea; any other Grade \>=3 non-hematologic toxicity except alopecia or fatigue;any grade toxicity requiring two dose reductions or participant's discontinuation; Grade 4 neutropenia \<500 cells/mm\^3 for \>=5 consecutive days or febrile neutropenia; Grade 4 thrombocytopenia \<25,000 cells/mm\^3 or Grade 3 bleeding requiring platelet transfusion.

Secondary Outcome Measures

Name	Time	Method
Number of Participants Who Died, Experienced Adverse Events (AEs), Serious AEs (SAEs), Drug Related AEs and Discontinued Due to AEs	From start of study drug therapy up to 30 days after the last dose.	AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to an AE were recorded. Drug-related AEs: events with a relationship to the study therapy of certain; probable; possible; not likely or unrelated.
Number of Participants With Grade 3 or 4 Hematology Abnormalities	From start of study drug therapy up to 30 days after the last dose.	Hematology abnormalities were graded per the National Cancer Institute (NCI) Common. Terminology Criteria (CTC) version 3.0 criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Grade 3 and 4 criteria are as follows: Absolute Neutrophil Count (ANC): Grade 3: 0.5 - \<1.0\10\^9/L, Grade 4: \<0.5\10\^9/L; lymphocytes: Grade 3: 0.2 - \<0.5\10\^9/L, Grade 4: \<0.2\10\^9/L.
Number of Participants With Grade 3-4 Serum Chemistry Abnormalities	From start of study drug therapy up to 30 days after the last dose.	Abnormalities were graded according to the NCI CTC, version 3.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Grade 3 and 4 criteria are as follows: phosphorous: Grade 3: 1.0-\<2.0 mg/dL, Grade 4: \<1.0 mg/dL; calcium: Grade 3: 6.0-\<7.0 or \>12.5-13.5 mg/dL, Grade 4: \<0.6-\>13.5 mg/dL; magnesium: Grade 3: \>3.0 - 8.0 mg/dL or \>1.23 - 3.30 mmol/L, Grade 4: \>8.0 mg/dL or \>3.30 mmol/L; albumin: Grade 3: \<2 g/dL or \<20 g/L.
Most Frequent Grade 3-4 Hematology Abnormalities Occurring in >=10% Participants: Low Lymphocyte Count	From start of study drug therapy up to 30 days after the last dose.	Abnormalities were graded according to the NCI CTC, version 3.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Most frequent hematology Grade 3 and 4 abnormalities occurring in \>=10% participants were recorded. Grade 3 and 4 criteria are as follows: lymphocyte count: Grade 3: 0.2 - \<0.5\10\^9/L, Grade 4: \<0.2\10\^9/L.
Most Frequent Serum Chemistry Laboratory Abnormalities Occurring in >=10% Participants: High Magnesium	From start of study drug therapy up to 30 days after the last dose.	Abnormalities were graded according to the NCI-CTC, version 3.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening). Most frequent (\>=10%) serum laboratory abnormalities were recorded. The following definitions specify the NCI-CTC AE criteria for serum laboratory abnormalities in the data presented: magnesium: Grade 3: \>3.0 - 8.0 mg/dL or \>1.23 - 3.30 mmol/L, Grade 4: \>8.0 mg/dL or \>3.30 mmol/L.
Number of Participants With Clinically Meaningful Physical Examination Measures	From screening, Day 1 in each treatment course and at the end of study	Interim and final physical examinations were performed. The investigator used his/her clinical judgment to decide whether or not physical examination findings were clinically significant.
Number of Participants With Clinically Meaningful Vital Signs	From screening, Day 1 , 8, 15 and 22 in the 1st treatment course, Day 8 and 22 in the second and subsequent courses and at the end of study	Vital signs measurements (including blood pressure, body temperature and pulse rate) were recorded. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs were clinically significant.
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings	From screening Day -1, and at pre-dose, 1 and 4 hours (post-dose) on Days 1, 14 and 28 in first treatment course, at pre-dose, 1 and 4 hours (post-dose) during the second and fourth week in subsequent courses and at the end of study	Standard 12-lead ECG was used to record selected ECG parameters like RR interval (the time between the two R waves in ECG), PR interval (interval measured from the beginning of the P wave to the beginning of the QRS complex; QRS complex is the name for some of the deflections seen on a typical ECG)), QRS duration, QT interval (time between onset of ventricular depolarization and end of ventricular repolarization), QT interval corrected for heart rate using Bazett's (QTcB) and Fridericia's (QTcF) formulas.
Number of Participants With Clinically Significant Change in QT Interval Corrected for Heart Rate (QTcF)	Baseline, Day 1, Day 14 and Day 28	QT interval corrected for heart rate (QTcF) was assessed using triplicate 12-lead serial ECGs.
Maximum Plasma Concentration (Cmax) of Dasatinib	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28	Cmax was obtained from the plasma concentration versus time data after oral administration of dasatinib.
Area Under the Plasma-concentration-time Curve [AUC (INF)] of Dasatinib on Day 1	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Day 1	AUC(INF), area under the plasma concentration-time curve from zero to the last time of the last quantifiable concentration within the dosing interval was calculated for Day 1.
AUC[TAU] of Dasatinib	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28	Area under the plasma concentration-time curve within the dosing interval was determined. AUC(TAU), from time 0 to the time of the last measurable concentration (24 hours) was calculated for Day 1, 14, 28 respectively.
Time to Reach Maximum Observed Plasma Concentration of Dasatinib (Tmax)	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28	Tmax, time to reach maximum observed plasma concentration of dasatinib was obtained directly from the plasma concentration versus time data.
Terminal Elimination Half-life (T-half) of Dasatinib	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28	T-half of dasatinib was calculated using plasma concentration versus time data.
Accumulation Index (AI) of Dasatinib	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28	AI of Dasatinib was calculated as ratio of geometric mean of AUC(TAU) (area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration) on Day 14 or Day 28 on Day 1.
Mean Apparent Oral Clearance (CLo) of Dasatinib	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 14 and 28	Apparent oral clearance was obtained from the plasma concentration versus time data.
Mean Apparent Volume of Distribution (Vz/F) of Dasatinib	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 14 and 28	Apparent volume of distribution after oral dosing was obtained from plasma concentration versus time data.
Cmax of Metabolite BMS-582691	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28	Maximum plasma concentration was obtained from plasma concentration versus time data of metabolite (BMS-582691).
AUC (0-t) of Metabolite BMS-582691	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28	AUC (0-t) was calculated using plasma concentration values of metabolite at time 0 to the time of the last measurable concentration (t).
Tmax of the Metabolite BMS-582691	Blood samples were collected at 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 1, 14 and 28	Tmax of the metabolite was obtained using plasma concentration versus time data of metabolite BMS-582691.
Mean Urine Concentration of Urinary N-telopeptide Type 1 Collagen (NTx) Biological Marker	Urine samples were collected at baseline (Day -1) and 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 12 and 24 hours (post dose) on Days 14 and 28.	Urine NTx is a measure of bone metabolism. A decrease in the marker relative to baseline indicates a decrease in bone metabolism. Mean urine concentration of NTx biological marker was determined using enzyme linked immuno-sorbent assay (ELISA).
Mean Urine Concentration of Deoxypyridinoline (Dpyr) Biological Marker	Urine samples were collected at baseline (Day -1) and 0 hour (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6 12 and 24 hours post dose on Days 14 and 28	Urine levels of DPyr is a measure of bone resorption. A decrease in Dpyr relative to the baseline indicates decrease in bone metabolism. Mean urine concentration of Dpyr biological marker was determined using ELISA.
Mean Serum Concentration of Tartrate-resistant Acid Phosphatase Isoform 5b (TRACP-5b) Biological Marker	Serum samples were assessed at baseline (Day -1) and on Days 14 and 28	TRACP-5b is a measure of bone metabolism. A decrease in TRACP-5b relative to the baseline indicates decrease in bone metabolism. Serum TRACP-5b was quantified with enzyme-linked-immunosorbent serologic assay (ELISA).
Mean Serum Concentration of Bone Alkaline Phosphatase (BAP) Biological Marker	Serum samples were assessed on baseline (Day -1), and pre-dose on Days 14, 28	BAP is a measure of bone metabolism. A decrease in BAP relative to the baseline indicates decrease in bone metabolism. Serum BAP was quantified with ELISA.
Number of Participants With Sarcoma (Src) and Phosphorylated Src (pSRc) Protein Expression in Peripheral Blood Mononuclear Cells (PBMC)	Plasma samples were collected on baseline (Day -1), 0 hour (pre-dose), 1 and 4 hours (post-dose) on Days 1, 14 and 28	Src and pSrc protein expression was planned to be evaluated in PBMC for establishing PK/PD relationship between Src/pSrc protein expression in PBMC and exposure of BMS-354825.
Number of Participants With Complete Response (CR) or Partial Response (PR)	Within 4 weeks of first study drug administration, thereafter recorded every 4 or 8 weeks.	Tumor response was defined as the number of participants whose best response was CR or PR as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR: disappearance of all target/non-target lesions; PR: \>= 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.